Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Eytan Stein

Academic history

Eytan Stein received his medical degree from the Northwestern University Medical School, Chicago, IL, and completed a residency in the Northwestern Memorial Hospital, Chicago, IL. Dr Eytan is board certified in internal medicine, medical oncology and hematology.


Eytan M. Stein, MD, is the Chief of the Leukemia Service, Associate Attending Physician, Clinical Investigator, and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He conducts novel, Phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.

Dr. Stein led the clinical studies of the IDH2 inhibitor enasidenib and the IDH1 Inhibitor ivosidenib in patients with relapsed and refractory AML that led to their FDA approval in 2017 and 2018, respectively. He also leads a variety of Phase I clinical trials and serves as the lead investigator at Memorial Sloan Kettering for the BEAT AML master clinical trial. His current research focuses on elucidating mechanisms of resistance to IDH inhibitors and the use of menin inhibitors in patients with MLL-rearranged acute leukemia. His work has been published in journals such as Nature, Nature Medicine, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery and Blood. In addition, he serves on the Editorial Boards of Blood and Leukemia and Lymphoma.